atenolol has been researched along with Atherogenesis in 5 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 9.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "6 years) randomized to treatment with lacidipine or atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)." | 9.12 | Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. ( Baurecht, H; Bilo, G; Hennig, M; Mancia, G; Maronati, A; Omboni, S; Parati, G; Zanchetti, A, 2007) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 9.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 5.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "6 years) randomized to treatment with lacidipine or atenolol in the European Lacidipine Study on Atherosclerosis (ELSA)." | 5.12 | Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. ( Baurecht, H; Bilo, G; Hennig, M; Mancia, G; Maronati, A; Omboni, S; Parati, G; Zanchetti, A, 2007) |
| "The present post-hoc analyses were aimed at: describing the prevalence of the metabolic syndrome (MS) at baseline; investigating the effect of long-term antihypertensive therapy (and separately of atenolol and lacidipine) on MS prevalence; exploring whether MS at baseline influenced changes in carotid IMT and incidence of cardiovascular events during treatment; and describing the relations between MS and new cases of diabetes developing during treatment." | 5.12 | Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness. ( Baurecht, H; Carugo, S; Cuspidi, C; Hennig, M; Mancia, G; Tang, R; Zanchetti, A, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bombelli, M | 1 |
| Macchiarulo, M | 1 |
| Facchetti, R | 1 |
| Maggiolini, D | 1 |
| Cuspidi, C | 2 |
| Parati, G | 2 |
| Mancia, G | 3 |
| Grassi, G | 1 |
| Demir, Y | 1 |
| Bilo, G | 1 |
| Maronati, A | 1 |
| Omboni, S | 1 |
| Baurecht, H | 2 |
| Hennig, M | 2 |
| Zanchetti, A | 2 |
| Tang, R | 1 |
| Carugo, S | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
3 trials available for atenolol and Atherogenesis
| Article | Year |
|---|---|
Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Carotid Artery Diseases; Dihydro | 2019 |
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Blood Pressure Monitoring, Ambul | 2007 |
Prevalence and incidence of the metabolic syndrome in the European Lacidipine Study on Atherosclerosis (ELSA) and its relation with carotid intima-media thickness.
Topics: Aged; Antihypertensive Agents; Atenolol; Atherosclerosis; Calcium Channel Blockers; Carotid Arteries | 2007 |
2 other studies available for atenolol and Atherogenesis
| Article | Year |
|---|---|
The behaviour of some antihypertension drugs on human serum paraoxonase-1: an important protector enzyme against atherosclerosis.
Topics: Antihypertensive Agents; Aryldialkylphosphatase; Atenolol; Atherosclerosis; Humans; Lipoproteins, HD | 2019 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |